APGE
Apogee Therapeutics, Inc.74.78
-2.03-2.64%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.11BP/E (TTM)
-Basic EPS (TTM)
-4.38Dividend Yield
0%Recent Filings
8-K
Priced $70/share offering
Apogee Therapeutics priced a public offering of 5 million common shares at $70.00 per share on March 24, 2026, with underwriters—Jefferies, TD Securities, Stifel, and Guggenheim—exercising their full option for 750,000 more shares. Net proceeds will hit $377.4 million after fees, closing March 26. Cash bolsters the biotech's runway.
8-K
Zumilokibart sustains AD responses
Apogee Therapeutics released positive 52-week maintenance data from Phase 2 APEX Part A, showing zumilokibart (APG777) sustained EASI-75 responses in 75% (3-month dosing) and 85% (6-month dosing) of Week 16 responders, with deepening efficacy across lesions and itch in the full population. Safety aligned with class norms, featuring low serious adverse events (0.8%). Part B data due Q2 2026 supports Phase 3 start in 2H 2026. Dosing lasts half a year.
10-K
FY2025 results
Apogee Therapeutics posted FY2025 ended December 31, 2025 results typical for a clinical-stage biotech: no revenue, mounting R&D expenses on pipeline advancement, and a net loss driven by program development. Q4 saw positive momentum from zumilokibart's APEX Phase 2 Part A data in July 2025, delivering 71.0% EASI reduction versus placebo's 33.8% at week 16 (p<0.001, derived), with rapid itch relief and favorable safety. No quarterly financial breakdowns disclosed in the 10-K. Cash position stood at $1,757.9 million market value of non-affiliate equity as of June 30, 2025. Pipeline risks loom large. Clinical delays threaten momentum.
8-K
Pipeline advances, cash strong
Apogee Therapeutics reported full-year 2025 net loss of $255.8 million, up from $182.1 million, driven by R&D expenses rising to $214.7 million amid pipeline advances. Cash stands at $902.9 million, funding operations into 2H 2028. APEX Phase 2 Part A 52-week data due this month. Zumilokibart eyes Phase 3 in 2H 2026.
8-K
Positive zumilokibart asthma data
Apogee Therapeutics unveiled positive Phase 1b interim data for zumilokibart (APG777) in mild-to-moderate asthma patients, showing a single 720mg dose slashed FeNO by 45 ppb (60% from baseline) with durable suppression through 16 weeks—all patients—and 32 weeks for some. Well-tolerated, no serious AEs. Data bolsters expansion beyond AD amid packed 2026 readouts; $913M cash runs to 2H 2028. Forward-looking milestones carry trial risks.
IPO
Employees
Sector
Industry
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
ALDX
Aldeyra Therapeutics, Inc.
5.31+1.32
APLM
Apollomics Inc.
17.02+0.92
APLS
Apellis Pharmaceuticals, Inc.
25.31+0.75
APLT
Applied Therapeutics, Inc.
0.12+0.00
APRE
Aprea Therapeutics, Inc.
0.91-0.01
APVO
Aptevo Therapeutics Inc.
1.10+0.06
ATXS
Astria Therapeutics, Inc.
12.87-0.05
COEP
Coeptis Therapeutics Holdings,
14.43-0.66
QTTB
Q32 Bio Inc.
2.88-0.17